Publications by authors named "C Rua"

Background: Case reports suggest that calcitonin gene-related peptide monoclonal antibodies (CGRP mAbs) may trigger inflammatory flares in patients with autoimmune diseases.

Case Description: A 56-year-old woman with a history of severe migraines, experienced improvement in migraine frequency and intensity after starting fremanezumab 225 mg monthly. However, three months into treatment, she developed symmetric inflammatory polyarthralgias.

View Article and Find Full Text PDF

Platypnea-orthodeoxia syndrome (POS) is characterized by dyspnea due to a marked fall in blood oxygen saturation while assuming standing or sitting positions. It is a rare condition with an unknown prevalence. The triggering role may remain unclear in a considerable number of patients.

View Article and Find Full Text PDF
Article Synopsis
  • Post-mortem studies reveal that patients who died from COVID-19 often show brainstem damage, which may result from immune responses during and after the infection.
  • Symptoms such as fatigue, breathlessness, and chest pain in post-hospitalization COVID-19 patients may be linked to these brainstem abnormalities.
  • Using advanced MRI techniques, a study found increased susceptibility in key brainstem regions of COVID-19 survivors, indicating a correlation between these changes and the severity of their illness and recovery outcomes.
View Article and Find Full Text PDF

Eosinophilic vasculitis is a rare condition due to vascular damage and infiltration of eosinophils into tissues. Antineutrophil cytoplasmic antibody (ANCA), like perinuclear ANCA (p-ANCA), is common in the context of systemic vasculitis, but its association with illicit drug use is unusual. This case report showcases a distinctive scenario featuring a positive pANCA, prompting a meticulous examination of the interplay between vasculitic manifestations and drug abuse.

View Article and Find Full Text PDF

Neuroferritinopathy is a disorder of neurodegeneration with brain iron accumulation that has no proven disease-modifying treatments. Clinical trials require biomarkers of iron deposition. We examined brain iron accumulation in one presymptomatic FTL mutation carrier, two individuals with neuroferritinopathy and one healthy control using ultra-high-field 7T MRI.

View Article and Find Full Text PDF